<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">39963</article-id><article-id pub-id-type="doi">10.17816/onco39963</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">TEMOZOLOMIDE IN MALIGNANT ASTROCYTIC GLIOMAS</article-title><trans-title-group xml:lang="ru"><trans-title>ТЕМОЗОЛОМИД ПРИ ЗЛОКАЧЕСТВЕННЫХ АСТРОЦИТАРНЫХ ГЛИОМАХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Borisov</surname><given-names>K. E.</given-names></name><name xml:lang="ru"><surname>Борисов</surname><given-names>Константин Евгеньевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>konstantin9671@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sakayeva</surname><given-names>D. D.</given-names></name><name xml:lang="ru"><surname>Сакаева</surname><given-names>Д. Д.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Clinical Dispensary, Ministry of Health of the Republic of Bashkortostan</institution></aff><aff><institution xml:lang="ru">ГУЗ Республиканский клинический онкологический диспансер Минздрава Республики Башкортостан</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2012</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="en">NO1 (2012)</issue-title><issue-title xml:lang="ru">№1 (2012)</issue-title><fpage>41</fpage><lpage>48</lpage><history><date date-type="received" iso-8601-date="2020-07-22"><day>22</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, ООО "Эко-Вектор"</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/39963">https://rjonco.com/1028-9984/article/view/39963</self-uri><abstract xml:lang="en"><p>The review of literature provides information on the use of temozolomide in the treatment of malignant astrocytic gliomas. The drug is the standard chemotherapy for recurrent malignant gliomas, by being superior to other agents in relapse-free survival rates, without substantially affecting overall survival. Temozolomide is also a standard component of chemoradiotherapy for new-onset glioblastoma multiforme. A combination of temozolomide and other drugs does not outperform monotherapy with the former in most cases. However, there is its synergism with platinum preparations and the inhibitors of topoisomerase and integrin receptor, which makes it urgent to develop new treatments against for gliomas. Alternative temozolomide regimens may be useful in overcoming the resistance to the drug and in minimizing its toxicity.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре литературы представлены сведения об использовании темозоломида при злокачественных астроцитарных глиомах. Темозоломид является стандартом химиотерапии рецидивов злокачественных глиом, превосходя другие препараты по показателю безрецидивной выживаемости без существенного влияния на общую выживаемость. Темозоломид также является стандартным компонентом химиолучевого лечения впервые выявленной мультиформной глиобластомы. Комбинации темозоломида с другими препаратами в большинстве случаев не превосходят монотерапию темозоломидом. Однако отмечен его синергизм с препаратами платины, ингибиторами топоизомеразы, ингибиторами интегриновых рецепторов, что делает актуальным разработку новых схем лечения глиом. Альтернативные режимы назначения темозоломида могут быть полезны для преодоления резистентности к препарату и уменьшения его токсичности.</p></trans-abstract><kwd-group xml:lang="en"><kwd>malignant gliomas</kwd><kwd>temozolomide</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>злокачественные глиомы</kwd><kwd>темозоломид</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Roos W. P., Batista L. F., Naumann S. C. et al. // Oncogene. 2007. Vol. 26. P. 186-197.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nakasu S., Fukami T., Jito J., Matsuda M. // Surg. Neurol. 2007. Vol. 68, N 6. P. 603-608.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Qian C. C., Brent T. P. // Cancer Res. 1997. Vol. 57. P. 3672-3677.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Balana C., Carrato C., Ramirez J. et al. // Proc. Am. Soc. Clin. Oncol. 2008. Abstr. 2037.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Wong E. T., Hess K. R., Gleason M. J. et al. // J. Clin. Oncol. 1999. Vol. 17, N 8. P. 2572-2578.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Yung W. K., Albright R. E., Olson J. et al. // Br. J. Cancer. 2000. Vol. 83. P. 588-593.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Qian Z. Z., Wang H. Q., Liu X. M. et al. // Zhonghua Yi Xue Za Zhi. 2009. Vol. 89, N 29. P. 2059-2062.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kapelle A. C., Postma T. J., Taphoorn M. J. B. et al. // Neurology. 2001. Vol. 56. P. 118-120.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Brada M., Stenning S., Gabe R. et al. // J. Clin. Oncol. 2010. - Vol. 28, N 30. P. 4601-4608.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ziobro M., Rolski J., Grela-Wojewoda A. et al. // Neurol. Neurochir. Pol. 2008. Vol. 42, N 3. P. 210-215.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bower M., Newlands E. S., Bleehen N. M. et al. // Cancer Chemother. Pharmacol. 1997. Vol. 40, N 6. P. 484-488.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Harris M. T., Rosenthal M. A., Ashley D. L., Cher L. // J. Clin. Neurosci. 2001. Vol. 8, N 4. P. 325-327.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Brada M., Hoang-Xuan K., Rampling R. et al. // Ann. Oncol. 2001. Vol. 12, N 2. P. 259-266.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chang S. M., Theodosopoulos P., Lamborn K. et al. // Cancer. 2004. Vol. 100, N 3. P. 605-611.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yung W. K., Prados M. D., Yaya-Tur R. et al. // J. Clin. Oncol. - 1999. Vol. 17, N 9. P. 2762-2771.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Nishikawa R., Shibui S., Maruno M. et al. // Gan To Kagaku Ryoho. 2006. Vol. 33, N 9. P. 1279-1285.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Teixeira M. M., Garcia I., Portela I. et al. // Int. J. Clin. Pharmacol. Res. 2002. Vol. 22, N 1. P. 19-22.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Brandes A. A., Ermani M., Basso U. et al. // Oncology. 2002. Vol. 63, N 1. P. 38-41.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Trent S., Kong A., Short S. C. et al. // J. Neurooncol. 2002. - Vol. 57, N 3. P. 247-251.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Fine H. A., Dear K. B. G., Loeffler J. S. et al. // Cancer. - 1993. Vol. 71, N 8. P. 2585-2597.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Stewart L. A. // Lancet. 2002. Vol. 359. P. 1011-1018.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Brandes A. A., Vastola F., Basso U. et al. // Cancer. 2003. - Vol. 97, N 3. P. 657-662.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Brandes A. A., Nicolardi L., Tosoni A. et al. // Neuro-Oncology. 2006. Vol. 8, N 3. P. 253-260.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wedge S. R., Porteous J. K., Glaser M. G. et al. // Anticancer Drugs. 1997. Vol. 8. P. 92-97.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Stupp R., Dietrich P. Y., Ostermann Kraljevic S. et al. // J. Clin. Oncol. 2002. Vol. 20, N 5. P. 1375-1382.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Stupp R., Mason W. P., van den Bent M. J. et al. // N. Engl. J. Med. 2005. Vol. 352, N 10. P. 987-996.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Hegi M. E., Diserens A. C., Gorlia T. et al. // N. Engl. J. Med. 2005. Vol. 352, N 10. P. 997-1003.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Athanassiou H., Synodinou M., Maragoudakis E. et al. // J. Clin. Oncol. 2005. Vol. 23, N 10. P. 2372-2377.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Combs S. E., Gutwein S., Schulz-Ertner D. et al. // Strahlenther. Onkol. 2005. Bd 181, N 6. S. 372-377.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Sridhar T., Gore A., Boiangiu I. et al. // Clin. Oncol. (R. Coll. Radiol.). 2009. Vol. 21, N 1. P. 19-22.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Combs S. E., Wagner J., Bischof M. et al. // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 70, N 4. P. 987-992.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Minniti G., De Sanctis V., Muni R. et al. // J. Neurooncol. 2008. Vol. 88, N 1. P. 97-103.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>De Sanctis V., Mazzarella G., Osti M. F. et al. // Anticancer Drugs. 2006. Vol. 17, N 8. P. 969-975.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Vinjamuri M., Adumala R. R., Altaha R. et al. // J. Neurooncol. 2009. Vol. 91, N 2. P. 221-225.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Штефан А. Ю. Химиолучевое лечение злокачественных глиом головного мозгас применением тенипозида: Автореф. дис.. канд. мед. наук. Уфа, 2007.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Balzarotti M, Ciusani E., Calatozzolo C. et al. // Oncol. Res. - 2004. Vol. 14, N 7-8. P. 325-330.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Balana C., Ramirez J. L., Taron M. et al. // Clin. Cancer Res. 2003. Vol. 9, N 4. P. 1461-1468.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Balana C., Lopez-Pousa A., Berrocal A. et al. // J. Neurooncol. 2004. Vol. 70, N 3. P. 359-369.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Brandes A. A., Basso U., Reni M. et al. // J. Clin. Oncol. 2004. Vol. 22, N 9. P. 1598-1604.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Silvani A., Eoli M., Salmaggi A. et al. // J. Neurooncol. 2004. Vol. 66, N 1-2. P. 203-208.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Chua A. L., Rosenthal M. A., Wong S. S. et al. // Neuro-Oncology. 2004. Vol. 6, N 1. P. 38-43.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Glas M., Koch H., Hirschmann B. et al. // Oncology. 2007. - Vol. 72, N 5-6. P. 302-307.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Gruber M. L., Buster W. P. // Am. J. Clin. Oncol. 2004. Vol. 27, N 1. P. 33-38.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Fountzilas G., Karkavelas G., Kalogera-Fountzila A. et al. // Anticancer Res. 2006. Vol. 26, N 6. P. 4675-4686.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Newland E. S., Foster T., Zaknoen S. // Br. J. Cancer. 2003. - Vol. 89. P. 248-251.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Herrlinger U., Rieger J., Koch D. et al. // J. Clin. Oncol. 2006. Vol. 24, N 4. P. 412-417.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Baumann F., Bjeljac M., Kollias S. S. et al. // J. Neurooncol. 2004. Vol. 67, N 1-2. P. 191-200.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Riva M., Imbesi F., Beghi E. et al. // Anticancer Res. 2007. - Vol. 27, N 2. P. 1067-1071.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Kesari S., Schiff D., Henson J. W. et al. // Neuro-Oncology. 2008. Vol. 10, N 3. P. 300-308.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Groves M. D., Puduvalli V. K., Chang S. M. et al. // J. Neurooncol. 2007. Vol. 81, N 3. P. 271-277.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Groves M.J.D., Puduvalli V. K., Conrad C. A. et al. // J. Neurooncol. 2006. Vol. 80, N 1. P. 83-90.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Grossman S. A., Ye X., Piantadosi S. et al. // Clin. Cancer Res. - 2010. Vol. 16, N 8. P. 2443-2449.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Newlands E. S., Stevens M. F. G., Wedge S. R. et al. // Cancer Treat. Rev. 1997. Vol. 23. P. 35-61.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Tolcher A. W., Gerson S. L., Denis L. et al. // Br. J. Cancer. 2003. Vol. 23. P. 1004-1011.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Wong S., Rosenthal M. A., Dowling A. et al. // J. Clin. Neurosci. 2006. Vol. 13, N 1. P. 18-22.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Wick A., Felsberg J., Steinbach J. P. et al. // J. Clin. Oncol. 2007. Vol. 25, N 22. P. 3357-3361.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>DAmico A., Gabbani M., Dall’oglio S. et al. // J. Clin. Oncol. 2006. Vol. 24 (suppl.). P. 75s. Abstr. 1572.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Brandes A. A., Tosoni A., Cavallo G. et al. // Br. J. Cancer. 2006. Vol. 95. P. 1155-1160.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Neyns B., Chaskis C., Joosens E. et al. // Cancer Invest. 2008. Vol. 26. P. 269-277.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Strik H. M., Buhk J. H., Bock C. et al. // Proc. Am. Soc. Clin. Oncol. 2008. Abstr. 13016.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Jauch T., Hau P., Bogdahn U. et al. // J. Clin. Oncol. 2007. - Vol. 25 (suppl.). P. 83s. Abstr. 2034.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Perry J. R., Belanger K., Mason W. P. et al. // J. Clin. Oncol. - 2010. Vol. 28, N 12. P. 2051-2057.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Kong D. S., Lee J. I., Kim J. H. et al. // Neuro-Oncology. - 2010. Vol. 12, N 3. P. 289-296.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>DAgostino G., Balducci M., Anile C. et al. // J. Clin. Oncol. 2007. Vol. 25 (suppl.). P. 83s. Abstr. 2035.</mixed-citation></ref></ref-list></back></article>
